% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Augustin:178400,
      author       = {H. Augustin$^*$ and G. Y. Koh},
      title        = {{A}ntiangiogenesis: {V}essel {R}egression, {V}essel
                      {N}ormalization, or {B}oth?},
      journal      = {Cancer research},
      volume       = {82},
      number       = {1},
      issn         = {0008-5472},
      address      = {Philadelphia, Pa.},
      publisher    = {AACR},
      reportid     = {DKFZ-2022-00037},
      pages        = {15 - 17},
      year         = {2022},
      note         = {DKFZ-ZMBH Alliance / #EA:A190#},
      abstract     = {The concepts of antiangiogenic tumor therapy were pioneered
                      on the assumption that the inhibition of tumor angiogenesis
                      should lead to the complete regression of the
                      tumor-associated vasculature and thereby hold the tumor in
                      an avascular dormant state. Yet, clinical trials revealed
                      limited efficacy of angiogenesis inhibitors when used as
                      monotherapy. Instead, antiangiogenic drugs proved effective
                      to extend overall survival when used in combination with
                      chemotherapy. This counterintuitive observation-inhibition
                      of tumor vascularization should lead to less and not more
                      delivery of chemotherapy to the tumor-led to the concepts of
                      'vessel normalization.' This refers to the notion that
                      antiangiogenic drugs prune the most immature tumor vessels
                      and spare mature vessels, thereby resulting in a more
                      normal-appearing vasculature that leads to better access of
                      chemotherapy to the tumor. The concepts of vessel
                      normalization were first laid out in a landmark publication
                      in Cancer Research in 2004. More than 600 studies on
                      different aspects of vessel normalization have been
                      published since then. Nevertheless, it is to this day less
                      clear than ever to what extent vessel regression (leading to
                      tumor starvation) and vessel normalization (facilitating
                      chemotherapy) contribute to the clinical efficacy of
                      antiangiogenic tumor therapy. This 'Landmark Commentary'
                      puts the concepts of tumor vessel normalization in
                      historical context and develops thereupon some of the most
                      burning questions in the field of translational angiogenesis
                      research that need to be answered to further advance the
                      application of tumor vascular stroma reprogramming
                      therapies.See related article by Tong and colleagues, Cancer
                      Res 2004;64:3731-6.},
      cin          = {A190},
      ddc          = {610},
      cid          = {I:(DE-He78)A190-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34983784},
      doi          = {10.1158/0008-5472.CAN-21-3515},
      url          = {https://inrepo02.dkfz.de/record/178400},
}